TETERBORO, N.J., May 5, 2004 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced that David M. Zewe, Senior Vice President,
Diagnostic Testing Operations, and Laure E. Park, Vice President, Investor
Relations, are scheduled to speak at the Morgan Stanley Second Annual Global
Healthcare Unplugged Conference on Thursday, May 6, 2004, at The Mandarin
Oriental Miami, in Miami, Florida. The Quest Diagnostics presentation is
scheduled to begin at 10:30 a.m. Eastern Time.
The presentation will be webcast live during the conference and will be
available to registered investors on the following site:
http://customer.talkpoint.com/MORG007/050504a_cf/default.asp?entity=quest and
to the public on http://www.questdiagnostics.com. In addition, the archived
webcast will be available starting by the end of the day, and will be
available for 30 days.
Quest Diagnostics Incorporated is the nation's leading provider of
diagnostic testing, information and services, providing insights that enable
healthcare professionals to make decisions that improve health. The company
offers the broadest access to diagnostic testing services through its national
network of laboratories and patient service centers, and provides interpretive
consultation through its extensive medical and scientific staff. Quest
Diagnostics is the leading provider of esoteric testing, including gene-based
medical testing, and provides advanced information technology solutions to
improve patient care. Additional company information is available at:
www.questdiagnostics.com.
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2003 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
Laure Park (Investors), +1-201-393-5030, or Gary Samuels
(Media), +1-201-393-5700, both for Quest Diagnostics Incorporated
http://www.questdiagnostics.com